Alpha-2 Adrenergic Agonists in Children with Inattention, Hyperactivity and Impulsiveness (original) (raw)

• Cohen DJ, Young JG, Nathanson JA, et al. Clonidine in Tourette’s syndrome. Lancet 1979; 2(8142): 551–3
  Article CAS Google Scholar
• Gold MS, Redmond Jr DE, Kleber HD. Clonidine blocks acute opiate-withdrawal symptoms. Lancet 1978; 2(8090): 599–602
  Article CAS Google Scholar
• Riddle MA, Bernstein GA, Cook EH, et al. Anxiolytics, adrenergic agents, and naltrexone. J Am Acad Child Adolesc Psychiatry 1999; 38(5): 546–56
  Article CAS Google Scholar
• Arnsten AF, Steere JC, Hunt RD. The contribution of alpha 2-noradrenergic mechanisms of prefrontal cortical cognitive function. Potential significance for attention-deficit hyperactivity disorder. Arch Gen Psychiatry 1996; 53(5): 448–55
  CAS PubMed Google Scholar
• Arnsten AFT. Alpha-2 agonists in the treatment of ADHD. Medscape Psychiatry & Mental Health 2007 [online]. Available from URL: http://www.medscape.com/viewarticle/560074 [Accessed 2008 Aug 24]
• Wang M, Ramos BP, Paspalas CD, et al. Alpha2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex. Cell 2007; 129(2): 397–410
  Article CAS Google Scholar
• Arnsten AF, Cai JX, Goldman-Rakic PS. The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: evidence for alpha-2 receptor subtypes. J Neurosci 1988; 8(11): 4287–98
  Article CAS Google Scholar
• Hunt RD, Minderaa RB, Cohen DJ. Clonidine benefits children with attention deficit disorder and hyperactivity: report of a double-blind placebo-crossover therapeutic trial. J Am Acad Child Psychiatry 1985; 24(5): 617–29
  Article CAS Google Scholar
• MacDonald E, Kobilka BK, Scheinin M. Gene targeting-homing in on alpha 2-adrenoceptor-subtype function. Trends Pharmacol Sci 1997; 18(6): 211–9
  Article CAS Google Scholar
• Rubia K, Smith AB, Brammer MJ, et al. Right inferior prefrontal cortex mediates response inhibition while mesial prefrontal cortex is responsible for error detection. Neuroimage 2003; 20(1): 351–8
  Article Google Scholar
• Jakala P, Riekkinen M, Sirvio J, et al. Guanfacine, but not clonidine, improves planning and working memory performance in humans. Neuropsychopharmacology 1999; 20(5): 460–70
  Article CAS Google Scholar
• Arnsten AFT. Toward a new understanding of attention-deficit hyperactivity disorder pathophysiology: an important role for prefrontal cortex dysfunction. CNS Drugs 2009; 23Suppl. 1: 33–41
  Article CAS Google Scholar
• Balldin J, Berggren U, Eriksson E, et al. Guanfacine as an alpha-2-agonist inducer of growth hormone secretion— a comparison with clonidine. Psychoneuroendocrinology 1993; 18(1): 45–55
  Article CAS Google Scholar
• Sica DA. Centrally acting antihypertensive agents: an update. J Clin Hypertens 2007;9(5): 399–405
  Article CAS Google Scholar
• Sarlis NJ, Caticha O, Anderson JL, et al. Hyperadrenergic state following acute withdrawal from clonidine used at supra therapeutic doses. Clin Auton Res 1996; 6(2): 115–7
  Article CAS Google Scholar
• Westfall T, Westfall D. Adrenergic agonists and antagonists. In: Brunton L, Lazo J, Parker K, editors. Goodman & Gilman’s the pharmaceutical basis of therapeutics. New York (NY): McGraw-Hill, 2008: 237–96
  Google Scholar
• Connor DF, Fletcher KE, Swanson JM. A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1999; 38(12): 1551–9
  Article CAS Google Scholar
• Scahill L, Chappell PB, Kim YS, et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry 2001; 158(7): 1067–74
  Article CAS Google Scholar
• Tourette syndrome (TS) Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology 2002; 58(4): 527–36
  Article Google Scholar
• Cummings DD, Singer HS, Krieger M, et al. Neuropsychiatric effects of guanfacine in children with mild Tourette syndrome: a pilot study. Clin Neuropharmacol 2002; 25(6): 325–32
  Article CAS Google Scholar
• Palumbo DR, Sallee FR, Pelham Jr WE, et al. Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes. J Am Acad Child Adolesc Psychiatry 2008; 47(2): 180–8
  Article Google Scholar
• Handen BL, Sahl R, Hardan AY. Guanfacine in children with autism and/or intellectual disabilities. J Dev Behav Pediatr 2008; 29(4): 303–8
  Article Google Scholar
• Biederman J, Melmed RD, Patel A, et al. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 2008; 121(1): e73–84
  Article Google Scholar
• Sallee FR, McGough J, Wigal T, et al., for the SPD503 Study Group. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2009; 48(2): 155–65
  Article Google Scholar
• Scahill L, Erenberg G, Berlin CM, et al. Contemporary assessment and pharmacotherapy of Tourette syndrome. NeuroRx 2006; 3(2): 192–206
  Article CAS Google Scholar
• Multimodal Treatment Study of Children with Attention-Deficit/Hyperactivity Disorder (MTA) Cooperative Group. Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder: the Multi-modal Treatment Study of children with Attention-deficit/ hyperactivity disorder. Arch Gen Psychiatry 1999; 56: 1088–96
  Article Google Scholar
• Daviss WB, Patel NC, Robb AS, et al. Clonidine for attention-deficit/hyperactivity disorder: II. ECG changes and adverse events analysis. J Am Acad Child Adolesc Psychiatry 2008; 47(2): 189–98
  PubMed Google Scholar
• Hunt RD, Arnsten AFT, Asbell MD. An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1995; 34: 50–4
  Article CAS Google Scholar
• Chappell PB, Riddle MA, Scahill L, et al. Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette’s syndrome: preliminary clinical experience. J Am Acad Child Adolesc Psychiatry 1995; 34: 1140–6
  Article CAS Google Scholar
• Horrigan JP, Barnhill LJ. Guanfacine for treatment of attention-deficit hyperactivity disorder in boys. J Child Adolesc Psychopharmacol 1995; 5: 215–23
  Article Google Scholar
• DuPaul GJ, Ervin RA, Hook CL, et al. Peer tutoring for children with attention deficit hyperactivity disorder: effects on classroom behavior and academic performance. J Appl Behav Anal 1998; 31: 579–92
  Article CAS Google Scholar
• Aman MG, Singh NN, Stewart AW, et al. The Aberrant Behavior Checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic 1985; 89(5): 485–91
  CAS PubMed Google Scholar
• Scahill L, Aman MG, McDougle CJ, et al. A prospective open trial of guanfacine in children with pervasive developmental disorders. J Child Adolesc Psychopharmacol 2006; 16(5): 589–98
  Article Google Scholar
• Boreman CD, Arnold LE. Hallucinations associated with initiation of guanfacine. J Am Acad Child Adolesc Psychiatry 2003; 42(12): 1387
  Article Google Scholar
• Luthra V, Markov D, Ambrosini P. Does guanfacine cause hallucinations in children? J Child Adolesc Psychopharmacol 1999; 9(4): 313–4
  Article CAS Google Scholar
• Horrigan JP, Barnhill LJ. Guanfacine and secondary mania in children. J Affect Disord 1999; 54(3): 309–14
  Article CAS Google Scholar